HROW
Harrow Health, Inc.
HROW's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over HROW overall, supported by stronger fundamentals and lower modeled downside.
HROW Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Weak |
HROW's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HROW PE Valuation
HROW has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 26x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HROW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HROW to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.10 | — |
| Q3 2026 | -$0.75 | -$0.60 |
| Q2 2026 | -$0.97 | -$0.67 |
| Q1 2026 | -$0.38 | +$0.23 |
| Q4 2025 | -$0.14 | +$0.35 |
| Q3 2025 | -$0.15 | +$0.79 |
| Q2 2025 | -$0.30 | +$0.65 |
| Q1 2025 | -$0.61 | +$0.30 |
| Q4 2024 | -$0.49 | +$0.26 |
HROW lost $0.75 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HROW on earnings quality, reporting a profit while its opponent remains loss making.
HROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $99.3M | +39% |
| Q2 2026 | $70.7M | +11% |
| Q1 2026 | $44.2M | -7.6% |
| Q4 2025 | $89.1M | +33% |
| Q3 2025 | $71.6M | +45% |
| Q2 2025 | $63.7M | +30% |
| Q1 2025 | $47.8M | +38% |
| Q4 2024 | $66.8M | +84% |
HROW's revenue is growing: $99M last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -9 points |
| Q2 2026 | -16% | -34 points |
| Q1 2026 | -50% | -27 points |
| Q4 2025 | 18% | -1.8 points |
| Q3 2025 | 21% | +18 points |
| Q2 2025 | 18% | +15 points |
| Q1 2025 | -23% | -3.4 points |
| Q4 2024 | 19% | +33 points |
HROW's operating margin was 12% last quarter, down 9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HROW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HROW on profitability, with a higher operating margin.
HROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9M | -155% |
| Q2 2026 | -$10.2M | -$9.3M |
| Q1 2026 | -$9.2M | -147% |
| Q4 2025 | $8.1M | +$26.4M |
| Q3 2025 | $16.4M | +598% |
| Q2 2025 | -$969K | +$2.1M |
| Q1 2025 | $19.5M | +$24.2M |
| Q4 2024 | -$18.3M | -316% |
HROW's free cash flow was −$20M over the past year, against $17M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HROW on cash generation, producing positive trailing cash flow while its opponent burns cash.
HROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.2M shares |
| 1 year | -0.9% | -341K shares |
| 3 years | +12% | +4.3M shares |
| 5 years | +42% | +11.4M shares |
| Available history | +46% | +12.1M shares |
HROW has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 9.7x | High |
| Q4 2025 | 5.5x | High |
| Q3 2025 | 9.3x | High |
| Q2 2025 | 12.2x | High |
| Q1 2025 | 29.7x | High |
| Q4 2024 | 20.2x | High |
| Q4 2023 | 88.0x | High |
| Q3 2023 | 37.2x | High |
HROW's net debt is about 9.7 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 9.8 | Oversold |
HROW's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HROW PE vs Healthcare Sector
| Metric | HROW | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HROW has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.0 | 2.4% below |
| 20 week MA | $35.3 | 20% below |
| 50 week MA | $39.0 | 27% below |
| 100 week MA | $36.1 | 21% below |
| 200 week MA | $28.8 | 1.6% below |
HROW is in a downtrend: it's below all five of its weekly moving averages, and 1.6% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HROW on trend strength, trading above more of its moving averages.
HROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.88 | $5.78 | -27% |
| 2021 | $5.78 | $9.20 | +59% |
| 2022 | $9.20 | $14.2 | +54% |
| 2023 | $14.2 | $11.2 | -21% |
| 2024 | $11.2 | $33.5 | +199% |
| 2025 | $33.5 | $50.1 | +50% |
| 2026 YTD | $50.1 | $28.3 | -44% |
HROW is down 44% so far in 2026, after finishing higher in four of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HROW on returns for 2026, with the stronger performance.